BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10456294)

  • 1. Intra-individual variability and influence of urine collection period on dextromethorphan metabolic ratios in healthy subjects.
    Chládek J; Zimová G; Martínková J; Tůma I
    Fundam Clin Pharmacol; 1999; 13(4):508-15. PubMed ID: 10456294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity.
    Ducharme J; Abdullah S; Wainer IW
    J Chromatogr B Biomed Appl; 1996 Mar; 678(1):113-28. PubMed ID: 8861661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers.
    Min DI; Ku YM; Vichiendilokkul A; Fleckenstein LL
    Pharmacotherapy; 1999 Jun; 19(6):753-9. PubMed ID: 10391422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
    Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
    Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma.
    Chládek J; Zimová G; Beránek M; Martínková J
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):651-7. PubMed ID: 11214771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity.
    Kashuba AD; Nafziger AN; Kearns GL; Leeder JS; Gotschall R; Gaedigk A; Bertino JS
    Pharmacogenetics; 1999 Aug; 9(4):453-62. PubMed ID: 10780265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.
    McCune JS; Lindley C; Decker JL; Williamson KM; Meadowcroft AM; Graff D; Sawyer WT; Blough DK; Pieper JA
    J Clin Pharmacol; 2001 Jul; 41(7):723-31. PubMed ID: 11452704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?
    Yu A; Haining RL
    Drug Metab Dispos; 2001 Nov; 29(11):1514-20. PubMed ID: 11602530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.
    Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C
    Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates.
    Labbé L; Sirois C; Pilote S; Arseneault M; Robitaille NM; Turgeon J; Hamelin BA
    Pharmacogenetics; 2000 Jul; 10(5):425-38. PubMed ID: 10898112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine--application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition.
    Vengurlekar SS; Heitkamp J; McCush F; Velagaleti PR; Brisson JH; Bramer SL
    J Pharm Biomed Anal; 2002 Aug; 30(1):113-24. PubMed ID: 12151071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-point plasma or urine dextromethorphan method for determining CYP3A activity.
    Kuo BP; Hu OY; Hsiong CH; Pao LH; Chen TS; Hung CF
    Biopharm Drug Dispos; 2003 Dec; 24(9):367-73. PubMed ID: 14689465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein.
    Di Marco MP; Edwards DJ; Wainer IW; Ducharme MP
    Life Sci; 2002 Jul; 71(10):1149-60. PubMed ID: 12095536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.
    Funck-Brentano C; Boëlle PY; Verstuyft C; Bornert C; Becquemont L; Poirier JM
    Eur J Clin Pharmacol; 2005 Dec; 61(11):821-9. PubMed ID: 16315033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.
    von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Venkatakrishnan K; Schmider J; Harmatz JS; Shader RI
    J Pharm Pharmacol; 1998 Sep; 50(9):997-1004. PubMed ID: 9811160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of CYP2D6 in pregnancy.
    Wadelius M; Darj E; Frenne G; Rane A
    Clin Pharmacol Ther; 1997 Oct; 62(4):400-7. PubMed ID: 9357391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2D6 phenotyping with dextromethorphan.
    Wojtczak A; Rychlik-Sych M; Krochmalska-Ulacha E; Skretkowicz J
    Pharmacol Rep; 2007; 59(6):734-8. PubMed ID: 18195464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-performance liquid chromatography assay for simultaneous determination of dextromethorphan and its main metabolites in urine and in microsomal preparations.
    Bendriss EK; Markoglou N; Wainer IW
    J Chromatogr B Biomed Sci Appl; 2001 Apr; 754(1):209-15. PubMed ID: 11318417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of dextromethorphan N-demethylation activity as a biomarker for cytochrome P450 3A activity in man.
    Kawashima Y; Hagiwara M; Inoue Y; Someya T
    Pharmacol Toxicol; 2002 Feb; 90(2):82-8. PubMed ID: 12071430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.